


WHAT IS CLAIMED IS:

1. A pharmaceutical composition for the treatment of a malignant disease or condition in a mammal, the composition comprising a pharmaceutically acceptable excipient and a therapeutically effective dose of a compound of the formula



where **R<sub>1</sub>** is independently H or lower alkyl of 1 to 6 carbons;

**R<sub>2</sub>** and **R<sub>3</sub>** are independently H, lower alkyl of 1 to 6 carbons, F, Cl, Br, I, alkoxy of 1 to 6 carbons, or fluoroalkoxy of 1 to 6 carbons;

**m** is an integer 0 to 3;

**o** is an integer 0 to 4;

**n** is 0-5;

**Y** is phenyl, naphthyl, or a heteroaryl group selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, oxazolyl, thiazolyl, or imidazolyl, and

**B** is COOH, a pharmaceutically acceptable salt thereof, CONR<sub>6</sub>R<sub>7</sub> or COOR<sub>8</sub> where **R<sub>6</sub>** and **R<sub>7</sub>** independently are hydrogen or an alkyl group of 1 to 6 carbons and **R<sub>8</sub>** is alkyl of 1 to 6 carbons,


said composition being adapted to be used in combination with another chemotherapeutic agent effective for the treatment of the malignant disease or condition of the mammal.

1 2. A pharmaceutical composition in accordance with Claim 1 wherein  
2 the chemotherapeutic agent effective for the treatment of the malignant  
3 disease or condition of the mammal is interferon.

4 3. A pharmaceutical composition in accordance with Claim 2 adapted  
5 for the treatment of breast cancer.

6 4. A pharmaceutical composition in accordance with Claim 2 adapted  
7 for the treatment of leukemia.

8 5. A pharmaceutical composition in accordance with Claim 1 wherein  
9 the compound has the formula




17 where R<sub>1</sub> is H or methyl, R<sub>3</sub> is H or methyl, and R\*<sub>8</sub> is H, or lower  
18 alkyl of 1 to 3 carbons, or a pharmaceutically acceptable salt of said  
19 compound.

20 6. A pharmaceutical composition in accordance with Claim 5 wherein  
21 the chemotherapeutic agent effective for the treatment of the malignant  
22 disease or condition of the mammal is interferon.

23 7. A pharmaceutical composition in accordance with Claim 6 adapted  
24 for the treatment of breast cancer.

25 8. A pharmaceutical composition in accordance with Claim 5 adapted  
26 for the treatment of leukemia.

27 9. A pharmaceutical composition in accordance with Claim 1 wherein  
28 the compound has the formula



where  $\text{R}_8$  is H, alkyl of 1 to 3 carbons, or a pharmaceutically acceptable salt of said compound.


10. A pharmaceutical composition in accordance with Claim 9 wherein the chemotherapeutic agent effective for the treatment of the malignant disease or condition of the mammal is interferon.

11. A pharmaceutical composition in accordance with Claim 10 adapted for the treatment of breast cancer.

12. A pharmaceutical composition in accordance with Claim 10 adapted for the treatment of leukemia.

13. A pharmaceutical composition in accordance with Claim 9 where  $\text{R}_8$  is ethyl.


14. A method of treating a malignant disease or condition in a mammal in need of such treatment, the method comprising the steps of:  
administering to said mammal a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective dose of a compound of the formula



Sub AB  
cont.

0040852.031700  
25804960

- 1 where  $R_1$  is independently H or lower alkyl of 1 to 6 carbons;  
2  $R_2$  and  $R_3$  are independently H, lower alkyl of 1 to 6 carbons, F, Cl,  
3 Br, I, alkoxy of 1 to 6 carbons, or fluoroalkoxy of 1 to 6 carbons;  
4  $m$  is an integer 0 to 3;  
5  $o$  is an integer 0 to 4;  
6  $n$  is 0-5;  
7  $Y$  is phenyl, naphthyl, or a heteroaryl group selected from a group  
8 consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl;  
9 oxazolyl, thiazolyl, or imidazolyl;  
10  $B$  is  $COOH$ , a pharmaceutically acceptable salt thereof,  $CONR_6R_7$  or  
11  $COOR_8$  where  $R_6$  and  $R_7$  independently are hydrogen or an alkyl group of 1  
12 to 6 carbons and  $R_8$  is alkyl of 1 to 6 carbons, and  
13 co-administering to said mammal with said compound another  
14 chemotherapeutic agent effective for the treatment of the malignant disease or  
15 condition of the mammal  
16 15. A method in accordance with Claim 14 where the  
17 chemotherapeutic agent is interferon.  
18 16. A method in accordance with Claim 15 where the  
19 chemotherapeutic agent is human recombinant interferon  $\alpha$ , human  
20 recombinant interferon  $\beta$ , or human recombinant interferon  $\gamma$ .  
21 17. A method in accordance with Claim 16 where the malignant  
22 disease or condition treated is breast cancer or leukemia.  
23 18. A method in accordance with Claim 17 where the malignant  
24 disease or condition treated is acute myeloid leukemia.  
25 19. A method in accordance with Claim 14 wherein the compound has  
26 the formula



where  $R_1$  is H or methyl,  $R_3$  is H or methyl, and  $R^*_8$  is H, or lower alkyl of 1 to 3 carbons, or a pharmaceutically acceptable salt of said compound.


20. A method in accordance with Claim 19 where the chemotherapeutic agent is interferon.

21. A method in accordance with Claim 20 where the chemotherapeutic agent is human recombinant interferon  $\alpha$ , human recombinant interferon  $\beta$ , or human recombinant interferon  $\gamma$ .

22. A method in accordance with Claim 21 where the malignant disease or condition treated is breast cancer or leukemia.

23. A method in accordance with Claim 21 where the malignant disease or condition treated is acute myeloid leukemia.

24. A method in accordance with Claim 14 wherein the compound has the formula



1        where  $R_8$  is H, alkyl of 1 to 3 carbons, or a pharmaceutically acceptable  
2 salt of said compound.

3        25. A method in accordance with Claim 24 where  $R_8$  is ethyl.

4        26. A method in accordance with Claim 25 where the  
5 chemotherapeutic agent is interferon.

6        27. A method in accordance with Claim 26 where the  
7 chemotherapeutic agent is human recombinant interferon  $\alpha$ , human  
8 recombinant interferon  $\beta$ , or human recombinant interferon  $\gamma$ .

9        28. A method in accordance with Claim 27 where the malignant  
10 disease or condition treated is breast cancer or leukemia.

11       29. A method in accordance with Claim 27 where the malignant  
12 disease or condition treated is acute myeloid leukemia.

13       30. A method in accordance with any of the Claims 24 through 29  
14 wherein a daily dose of approximately 50 mg to 500 mg of the compound is  
15 administered to the mammal.

add B3

09640852-001700